

# Comparison of Clinical Symptoms between Group A and Group C Rotavirus Infections in Japan

Ken Sugata<sup>1,5\*</sup>, Kimberly Foytich<sup>1</sup>, Sung-Sil Moon<sup>1</sup>, Maureen Metcalfe<sup>2</sup>, Tetsushi Yoshikawa<sup>3</sup>, Naoko Nishimura<sup>4</sup>, Takao Ozaki<sup>4</sup> and Baoming Jiang<sup>1</sup>

<sup>1</sup>Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

<sup>2</sup>Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA

<sup>3</sup>Fujita Health University, Toyoake, Aichi, Japan

<sup>4</sup>Konan Kosei Hospital, Konan, Japan

<sup>5</sup>Department of Pediatrics, Fujita Health University, The Second Teaching Hospital, Otobashi Nakagawaku, Nagoya-shi, Aichi, Japan

\*Corresponding author: Ken Sugata, Department of Pediatrics, Fujita Health University, the Second Teaching Hospital, Otobashi Nakagawaku, Nagoya-shi, Aichi, Japan, E-mail: [ksugata@fujita-hu.ac.jp](mailto:ksugata@fujita-hu.ac.jp)

Received date: 17 May 2016; Accepted date: 14 Jun 2016; Published date: 18 Jun 2016.

Citation: Sugata K, Foytich K, Moon S-S, Metcalfe M, Yoshikawa T, et al. (2016) Comparison of Clinical Symptoms between Group A and Group C Rotavirus Infections in Japan. *J Emerg Dis Virol* 2(4): doi <http://dx.doi.org/10.16966/2473-1846.122>

Copyright: © 2016 Sugata K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

**Background:** Group C rotavirus (GCRV) has been detected in both sporadic cases and outbreaks of gastroenteritis (GE) throughout the world. However, the epidemiology of GCRV infection is still poorly understood because detection methods are not readily available compared to group A rotavirus (GARV).

**Objective:** We assessed molecular and enzyme-linked immune assays for the diagnosis of sporadic GCRV infection and investigated clinical symptoms including extraintestinal findings.

**Study design:** Thirty hospitalized children with acute GE were enrolled for the diagnosis of GARV and GCRV, and the comparison of clinical symptoms between the two groups.

**Results:** Of 30 rectal swab specimens tested, 24 were positive for rotavirus; 6 were positive for GCRV by enzyme immunoassay, RT-PCR and electron microscopy, whereas 16 were positive for GARV. Although Vesikari severity scores for GE were not significantly different between GCRV and GARV patients, extraintestinal complications such as seizures and hepatitis were not seen in GCRV patients.

**Conclusion:** GCRV sporadic infection was seen at the same time of GARV prevalence in the same area. A combination of different assays is needed for more accurate diagnosis of GCRV infection.

**Keywords:** Rotavirus; Gastroenteritis; Transaminase levels; Polyacrylamide gel electrophoresis

**Abbreviations:** ELISA: Enzyme Linked Immunosorbent Assay; GARV: Group A Rotavirus; GCRV: Group C Rotavirus; PCR: Polymerase Chain Reaction.

## Introduction

Rotavirus (RV) is the major cause of gastroenteritis (GE) in young children worldwide. RVs have been subdivided into seven groups (A to H) on the basis of their dsRNA electrophoretic types and antigenicity [1]. In humans, Group A rotavirus (GARV) was first identified in 1973 [2]. GARVs have been associated with high morbidity and mortality with an estimated 215000 deaths occurring annually [3], causing infants severe dehydration because of fever and frequently diarrhoea and vomiting. Furthermore it has been widely known that GARV GE is sometimes complicated by high fever, elevated transaminase levels [4,5], seizures [6,7] and encephalopathy [8,9] which may be caused by systemic viral infection. In Japan, the most common viruses responsible for acute GE are *norovirus*, GARV and *sapovirus* [10]. Group C rotavirus (GCRV) was first identified in swine in 1980 [11]. Human GCRV infection was first detected in Rio de Janeiro, Brazil in 1983 [12]. Subsequently, GCRV has been detected in both sporadic cases and outbreaks of GE throughout the world. The detection rate of GCRV infection has been reported, ranging from 0.23% to 6.9% in many countries [13-17]. In Japan, GCRV was

first reported in 1986 [18] and the positive rates in sporadic cases and outbreaks ranged from 2.7-13.3% [19]. GARV antigen detection using commercial ELISA kit is fast, easy and handy; however, an ELISA kit for the detection of GCRV is not still available. Many assays and molecular techniques such as electron microscopy, ELISA, reverse transcription-polymerase chain reaction (RT-PCR), polyacrylamide gel electrophoresis (PAGE) and reverse passive hemagglutination (RPHA), have been able to detect GCRV in several studies. There is not gold standard for GCRV detection, then due to the lack of sensitive and specific diagnostic assays, the epidemiology and disease burden of GCRV have not been fully established. In addition, little is known about GCRV clinical symptoms in humans; GCRV is generally believed to be associated with milder GE or asymptomatic infection in children and adults [20]. Therefore, it is very important to accumulate samples and information, even from sporadic cases. In the present study, we assessed molecular and enzyme-linked immune assays for the diagnosis of sporadic GCRV infection in a small group of non-immunocompromised children in Japan. We further compared clinical symptoms of GE between GARV and GCRV infection in these children.

## Materials and Methods

### Patient characteristics and sample collection

Thirty children (17 boys and 13 girls) under 10 years old, hospitalized at the pediatric department in Konan Kosei Hospital between March and June of 2009 with acute GE, were enrolled in this study. At the time of admission, a rectal swab sample was collected from each patient. In addition, pair of serum samples for RV antigen testing were collected both at the time of admission (Day 1) and discharge from Day 3 to Day 8, several days later. Samples were stored at  $-70^{\circ}\text{C}$  before being shipped on dry ice to the Centers for Disease Control and Prevention (CDC) in Atlanta, USA. Clinical manifestations of the subjects were ascertained retrospectively from medical records. We assessed the severity of disease by using a 20-point Vesikari scoring system [21]. Written informed consent was obtained from all parents and the children were then enrolled using the study protocol approved by the institutional review boards of the Fujita Health University (08-177). The CDC tested coded specimens with unique identifiers for anonymity under a non-disclosure agreement, which unequivocally prohibits the release of personally identifiable information about participants.

In addition, rectal swab samples from all patients were cultured to detect enteric bacteria.

### ELISAs

All 30 rectal swab samples were screened for GARV and adenovirus by using commercial ELISA kits (Rotaclone and Adenoclone; both from Meridian Bioscience, Inc., Cincinnati, OH). All stool specimens were tested for GCRV antigen using an in-house immunoassay with reagents specific to the porcine GCRV Cowden strain [13]. Briefly, 96-well plates (Nalgen Nunc International) were coated with porcine anti-GCRV serum (U340; dilution 1:2000) or normal porcine serum (Z1329; dilution 1:2000) in coating buffer (35 mM  $\text{NaHCO}_3$ , 15 mM  $\text{Na}_2\text{CO}_3$ , pH 9.6). After washing with phosphate buffered saline (PBS)-0.05% Tween (PBST) plates were incubated with blotto. Plates were incubated with diluted stool samples (dilution 1:10) or GCRV virus-like particles (VLPs, positive control). Plates were incubated with rabbit hyper immune serum to human GCRV VLPs (CD94; dilution 1:4000) Plates were incubated with horseradish peroxidase-goat anti-rabbit IgG (KPL, Gaithersburg, MD, USA) diluted 1:5000, for 1 hour at  $37^{\circ}\text{C}$ . Reactions were stopped with 1 N HCl and the optical density (OD) was read at 450 nm with an ELISA reader (MRX Revelation, Dynex Technologies, Chantilly, VA). A sample was considered positive if the ratio of absorbance with the hyperimmune serum (U340) over the normal serum (Z1329) was  $>1.7$  [13].

### PCRs and sequence analysis of GCRV

All rectal swab specimens were tested for GCRV by RT-PCR and nested PCR with previously published specific primers for the *VP6* and *VP7* genes of human GCRV (17, 22). *VP6* and *VP7* genes were amplified using primers BMJ44 and BMJ145, and BMJ13 and BMJ107, respectively. Nested PCR was done for *VP6* and *VP7* using primers BMJ43 and BMJ144, BMJ27 and BMJ143, respectively. The nested PCR was performed as RT-PCR without reverse transcription and with annealing temperatures of  $53^{\circ}\text{C}$  and  $48^{\circ}\text{C}$  for *VP6* and *VP7* genes, respectively. The PCR products of GCRV *VP6* and *VP7* genes were purified by mini columns (QIAquick, Qiagen, Valencia, CA) and sequenced using the ABI-PRISM Big Dye terminator Cycle Sequencing kit and an ABI prism 310 Genetic analyzer (Applied Biosystems Inc. Foster City, CA).

### G and P typing and sequence analysis of GARV

G genotypes of GARV in rectal swab sample were determined by using RT-PCR with previously published specific primers 9con1L and VP7-RDg [23]. The second amplification was performed from the first PCR

product (1025 bp) using the 9con1L primer and a cocktail of G type-specific primers (9T-1, 9T-2, 9T-3P, 9T-4 and 9T-B) for *VP7* G1-G4 and G9, respectively. The amplicon sizes for G1, G2, G3, G4 and G9 strains were 158 bp, 224 bp, 466 bp, 403 bp and 110 bp, respectively. *VP4* P typing was performed in the same manner as *VP7* gene assay with previously published specific primers Con2 and Con3 [23]. The second amplification was performed from the first PCR product (877 bp) using the Con3 primer and a cocktail of P type-specific primers (2T-1, 3T-1 and 1T-1) for P4, P6 and P8, respectively [24]. The amplicon sizes for P4, P6 and P8 strains were 484 bp, 268 bp, 346 bp, respectively.

### Electron microscopy (EM)

The rectal swabs in 10% PBS were examined by negative stain electron microscopy using two different techniques. First, 2 l of 1:10 diluted stool suspension was pipetted onto a 1% alcian blue treated formvar-carbon coated 300 mesh nickel grid (EMS Cat. No. FCF300-Ni). Samples were incubated overnight on grids in a refrigerator at  $4^{\circ}\text{C}$ . Sample were then blotted, rinsed with  $3.5\ \mu\text{l}$  of 1% bacitracin [25], blotted and stained with  $3.5\ \mu\text{l}$  of 5% ammonium molybdate (pH 6.9) with 1% trehalose (w/v) [26]. The stain was immediately blotted after applying and the grid was then allowed to air dry prior to viewing at the transmission electron microscope (120 kV, BioTwin, FEI, Hillsboro, OR). If virus was not observed utilizing the first method, a second method was used to concentrate the samples onto the grids. Again, a 1% alcian blue treated grid was placed in an adapter located in an Ultra-Clear™ Beckman Airfuge® polyethylene terephthalate micro centrifuge tube (Beckman Coulter, Inc., Fullerton, CA Cat. No.345843; 5 mm  $\times$  20 mm). The grid and adapter were submerged in 80-90  $\mu\text{l}$  of 1:10 diluted stool suspension. The samples were then ultra-centrifuged at 20-24 pounds per square inch using a Beckman Airfuge® (Beckman Coulter, Inc., Fullerton, CA). After 10 minutes, the grids were blotted and stained as described above.

A sample that tested positive by more than two independent diagnostic assays was considered positive for GCRV.

### Statistical analysis

Statistical analyses among clinical variables were performed using SPSS version 21 (IBM, Armonk, NY). Mann-Whitney U test procedure was employed to analyze mean variables such as age, duration of stay, Vesikari severity score (0-20 points; severe  $>11$  points), and duration of individual clinical symptoms (e.g., fever and vomiting) between GCRV and GARV groups. Gender and presence of hepatitis and convulsion in patients with GCRV and GARV GE were compared using Fisher's exact probability test. In all comparisons, a *p*-value  $< 0.05$  (two-tailed) was considered statistically significant.

In this study, hepatitis was defined as elevated transaminase levels (alanine amino transferase: 50 IU/L). Instead, convulsion was defined as a cerebral paroxysm without signs of central nervous system infection, which has violent muscle contractions and loss of alertness with or without fever during GE.

### Results

All 30 patients were generally healthy before developing GE. The mean duration for each patient's hospital stay was  $7.1 \pm 1.6$  days. The patients had a mean Vesikari score of  $12.9 \pm 2.4$  points; 25 had a high severity of GE. Of the 30 rectal swab samples tested by ELISA, 16 were positive for GARV. Fourteen of the 16 ELISA-positive samples were G and P typed by RT-PCR; Eight patients were infected with G1P, two with G9P, two with G3P, and one with mixed G1/3P [8]. One sample was G and P non typeable.

We detected GCRV antigen in 9f the 30 rectal swab samples by ELISA. ELISA-positive specimens were then tested by RT-PCR using primers

specific to GCRV VP6 and VP7 genes and 5 specimens were positive (Table 1). We further examined ELISA-positive samples by EM. This positivity was confirmed by EM in three PCR positive samples containing RV or RV-like particles; 2 PCR positive samples had no detectable particles by EM vice versa 1 PCR negative samples resulted positive by EM (Figure 1). In general, GCRV particles were sparse and of poor structural integrity when compared with those of GARV. Thus, of 30 patients examined, 16 were positive for GARV, 6 positive for GCRV, respectively and 8 were negative for both GARV and GCRV. In 8 rotavirus-negative samples, 2 were positive for salmonella, 1 was positive for campylobacter, 1 for adenovirus, and 4 had no pathogens detected. There was no mixed infection with GARV and GCRV.


We next compared clinical symptoms, including extra intestinal symptoms, between patients infected with GARV and GCRV (Table 2). There was no significant difference in the mean age of the patients between the two groups (1.2 ± 0.5 years in GARV group, 2.0 ± 2.2 years in GCRV group; P=0.747). Though more boys than girls were apparently infected with GARV, there was no significant difference in gender between GARV- and GCRV-infected patients (P=0.334). In terms of clinical symptoms, there was no significant difference in duration of hospital stay, Vesikari severity score, and GE symptoms (vomiting, diarrhoea and fever) between the two groups. Although GARV patients appeared to have significantly longer duration of diarrhoea rather than GCRV patients (P=0.021). Of note, GARV patients appeared to be more likely to develop hepatitis than GCRV patients (P=0.046). Only patients with GARV infection had documented convulsions, no patients with GCRV infection had any convulsions. All patients with documented convulsions recovered from acute GE and were discharged without any sequelae.

## Discussion

In the present study, 6 of 30 patients were confirmed GCRVs positive by more than two independent diagnostic assays. Although EM might not be specific diagnostic assay to distinguish GARV and GCRV, it is still helpful to visually confirm RV and RV-like particles, which contained structures similar in morphology to RV cores. Supporting our results a previous report indicates that less than 10<sup>7</sup> virus particles per milliliter in

Patients	Age (year)	Gender	ELISA antigen	PCR		EM
				VP6*	VP7*	
1	1	M	+	-	-	+
2	1	F	+	+	+	+/-**
3	6	M	+	+	+	+
4	1	M	+	+	+	-
5	0.8	F	+	+	+	-
6	3	F	+	+	+	+
7	0	M	+	-	-	-
8	1	F	+	-	-	-
9	3	F	+	-	-	-

**Table 1:** Detection of GCRV in fecal samples of children with diarrhea  
\*PCR products were confirmed by DNA sequence analysis  
\*\*Samples contained structures that were similar in morphology to RV cores



**Figure 1:** Electron micrographs of GCRV particles in rectal swab samples of children with diarrhea. Panels A, B and C: complete GCRV particle in samples from patients 1, 3 and 6. Bar=100 nm

	GARV(n=16)	GCRV (n=6)	P value
Age (year)	1.2 ± 0.5	2.0 ± 2.2	0.747
Gender			
Male	12	3	0.334
Female	4	3	
Duration of hospital stay (day)	7.4 ± 1.8	6.8 ± 1.2	0.367
Vesikari score (point)	13.7 ± 1.8	12.5 ± 2.6	0.407
Individual symptoms			
Vomiting (day)	3.0 ± 1.6	1.7 ± 1.2	0.115
(times/day)	5.5 ± 5.9	4.2 ± 3.4	0.971
Diarrhea (day)	6.4 ± 2.1	4.0 ± 2.1	0.021*
(times/day)	5.3 ± 3.5	4.7 ± 3.7	0.693
Fever (day)	1.8 ± 1.9	1.0 ± 0.6	0.541
Hepatitis			
Yes	9	0	0.046
No	7	6	
Convulsion			
Yes	4	0	0.541
No	12	6	

**Table 2:** Comparison of demographic data and clinical symptoms in children with GARV and GCRV infection

the original specimen would not likely be detected by EM [27]. RV or RV-like particles were identified by EM in 3 of the 6 rectal swabs that tested positive for GCRV by ELISA or PCR. In the case of patient 1, although both VP6 and VP7 RNA were not detected by PCR, RV particles were observed by EM and GCRV antigen was detected by ELISA. Patients 4 and 5 tested positive for GCRV by ELISA and PCR but negative by EM. These findings agree with previous reports showing that GCRVs are fragile and are often present in empty- or core-like particles [28,29], possibly due to their structural instability in the gut or damage during storage and shipment. These data suggest that rectal swab samples could be used to identify RV when it is difficult to collect stool samples from GE patients.

Moreover, our study suggested that ELISA had almost the same sensitivity of RT-PCR but it was less specific than RT-PCR for detecting GCRV in rectal swabs. This indicates that ELISA is an appropriate and useful tool to screen GCRV. However formation of empty capsids or structural instability of the particle reduce the detection rate of RNA by RT-PCR or PAGE, a relatively larger amount of viral proteins than genome may be available for the detection as previously reported [28-34]. That explains why more than two methods could be helpful to increase detection rate of GCRV.

## Conflict of Interest

The observations and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## References

- Molinari BL, Lorenzetti E, Otonel RA, Alfieri AF, Alfieri AA (2014) Species H rotavirus detected in piglets with diarrhea, Brazil, 2012. *Emerg Infect Dis* 20: 1019-1022.
- Bishop RF, Davidson GP, Holmes IH, Ruck BJ (1973) Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. *Lancet* 2: 1281-1283.
- Tate JE, Burton AH, Boschi-Pinto C, Parashar UD (2016) Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. *Clin Infect Dis* 62: S96-S105.
- St Geme JW 3rd, Hyman D (1988) Hepatic injury during rotavirus infections. *J Pediatr* 113: 952-953.



5. Teitelbaum JE, Daghistani R (2007) Rotavirus causes hepatic transaminase elevation. *Dig Dis Sci* 52: 3396-3398.
6. Kawano G, Oshige K, Syutou S, Koteda Y, Yokoyama T, et al. (2007) Benign infantile convulsions associated with mild gastroenteritis: a retrospective study of 39 cases including virological tests and efficacy of anticonvulsants. *Brain Dev* 29: 617-622.
7. Chung B, Wong V (2007) Relationship between five common viruses and febrile seizure in children. *Arch Dis Child* 92: 589-593.
8. Kirton A, Busche K, Ross C, Wirrell E (2005) Acute necrotizing encephalopathy in Caucasian children: two cases and review of the literature. *J Child Neurol* 20: 527-532.
9. Karampatsas K, Spyridou C, Morrison IR, Tong CY, Prendergast AJ (2015) Rotavirus-associated mild encephalopathy with a reversible splenic lesion (MERS)-case report and review of the literature. *BMC Infect Dis* 15: 446.
10. National Institute of Infectious Diseases(NIID) (2014) Infectious Agents Surveillance Report (IASR) 35: 63-34.
11. Saif LJ, Bohl EH, Theil KW, Cross RF, House JA (1980) Rotavirus-like, calicivirus-like, and 23-nm virus-like particles associated with diarrhea in young pigs. *J Clin Microbiol* 12: 105-111.
12. Pereira HG, Leite JP, Azeredo RS, de Farias V, Suttmoller F (1983) An atypical rotavirus detected in a child with gastroenteritis in Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz* 78: 245-250.
13. Moon S, Humphrey CD, Kim JS, Baek LJ, Song JW, et al. (2011) First detection of group C rotavirus in children with acute gastroenteritis in South Korea. *Clin Microbiol Infect* 17: 244-247.
14. Bányai K, Jiang B, Bogdán A, Horváth B, Jakab F, et al. (2006) Prevalence and molecular characterization of human group C rotaviruses in Hungary. *J Clin Virol* 37: 317-322.
15. Medici MC, Abelli LA, Martinelli M, Martella V, Dettori G, et al. (2009) Molecular characterization of group C rotaviruses detected in children in Italy. *J Clin Virol* 44: 62-65.
16. Luchs A, Morillo SG, de Oliveira CM, Timenetsky Mdo C (2011) Monitoring of group C rotavirus in children with acute gastroenteritis in Brazil: an emergent epidemiological issue after rotavirus vaccine? *J Med Virol* 83: 1631-1636.
17. Jiang B, Dennehy PH, Spangenberg S, Gentsh JR, Glass RI (1995) First detection of group C rotavirus in fecal specimens of children with diarrhea in United States. *J Infect Dis* 172: 45-50.
18. Oseto M, Yamashita Y, Okuyama M, Kuwabara H, Inoue H (1986) Detection of atypical rotaviruses by polyacrylamide gel electrophoresis [in Japanese]. *J Clin Exp Med* 136: 223-224.
19. Phan TG, Nishimura S, Okame M, Nguyen TA, Khamrin P, et al. (2004) Virus diversity and an outbreak of group C rotavirus among infants and children with diarrhea in Maizuru city, Japan during 2002-2003. *J Med Virol* 74: 173-179.
20. Abid I, Guix S, Aouni M, Pintó R, Bosch A (2007) Detection and characterization of human group C rotavirus in the pediatric population of Barcelona, Spain. *J Clin Virol* 38: 78-82.
21. Ruuska T, Vesikari T (1990) Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. *Scand J Infect Dis* 22: 259-267.
22. Sánchez-Fauquier A, Roman E, Colomina J, Wilhelmi I, Glass RI, et al. (2003) First detection of group C rotavirus in children with acute diarrhea in Spain. *Arch Virol* 148: 399-340.
23. Das BK, Gentsch JR, Cicirello HG, Woods PA, Gupta A, et al. (1994) Characterization of rotavirus strains from newborns in New-Delhi, India. *J Clin Microbiol* 32: 1820-1822.
24. Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, et al. (1992) Identification of group A rotavirus gene 4 types by polymerase chain reaction. *J Clin Microbiol* 30: 1365-1373.
25. Gregory DW, Pirie BJ (1973) Wetting agents for biological electron microscopy. I. General considerations and negative staining. *J Microsc* 99: 251-255.
26. Harris JR, Bhella D, Adrian M (2006) Recent developments in negative staining for transmission electron microscopy. *Microsc Anal* 20: 5-9.
27. Doane FW, Anderson N (1977) Electron and Immunoelectron Microscopy. In *Comparative Diagnosis of Viral Diseases*. Academic Press, New York 11: 505-539.
28. Esona MD, Humphrey CD, Dennehy PH, Jiang B (2008) Prevalence of group C rotavirus among children in Rhode Island, United States. *J Clin Virol* 42: 221-224.
29. Yee EL, Jiang B, Kendall RS, Humphrey C, Glass RI (2006) Group C rotavirus in a pediatric kidney transplant patient with diarrhea. *J Clin Virol* 36: 306-308.
30. Steyer A, Poljsak-Prijatelj M, Bufon T, Sedmak M, Vidmar L, et al. (2006) First detection of group C rotavirus in patients with gastroenteritis in Slovenia. *J Med Virol* 78: 1250-1255.
31. Kuzuya M, Fujii R, Hamano M, Yamada M, Shiozaki K, et al. (1998) Survey of human group C rotavirus in Japan during the winter of 1992-1993. *J Clin Microbiol* 36: 6-10.
32. Nilsson M, Svenungsson B, Hedlund KO, Uhnoo I, Lagergren A, et al. (2000) Incidence and genetic diversity of group C rotavirus among adults. *J Infect Dis* 182: 678-684.
33. Sugata K, Taniguchi K, Yui A, Miyake F, Suga S, et al. (2008) Analysis of Rotavirus Antigenemia and Extraintestinal Manifestations in Children with Rotavirus Gastroenteritis. *Pediatr* 122: 392-397.
34. Lymch M, Lee B, Azimi P, Gentsch J, Glaser C, et al. (2001) Rotavirus and central nervous system symptoms: cause or contaminant? case reports and review. *Clin Infect Dis* 33: 932-938.